Palonosetron Macure

Palonosetron, the active ingredient in Palonoset3, is a medication presented as a sterile injectable solution for intravenous use. It is used to prevent nausea and vomiting associated with chemotherapy and postoperative settings in adult patients.

GNH USA supplies Palonoset3 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist indicated for the prevention of nausea and vomiting in several clinical contexts.

- Chemotherapy‑induced nausea and vomiting (CINV): provides long‑lasting protection for up to 72 hours after chemotherapy. - Post‑operative nausea and vomiting (PONV): reduces the incidence of nausea and vomiting following surgery. - Radiotherapy‑induced nausea and vomiting: helps control nausea associated with radiation treatment. - Anticipatory nausea and vomiting: lessens nausea that patients may experience before a known emetic stimulus. - Adjunctive therapy in highly emetogenic regimens: used together with other anti‑emetics for enhanced control. - Prevention of delayed vomiting after moderately emetogenic chemotherapy.

Palonosetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Constipation - Fatigue - Diarrhoea - Dizziness - Injection site erythema

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - QT interval prolongation - Serotonin syndrome (when combined with other serotonergic agents) - Cardiac arrhythmias - Severe hypotension - Neuro‑muscular weakness

When using Palonosetron, clinicians should consider several safety aspects.

- Cardiac monitoring: patients with known QT prolongation should be monitored. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Pregnancy: use only if clearly needed. - Breastfeeding: evaluate risk‑benefit before use. - Renal or hepatic impairment: dose adjustment may be required. - Store at ambient temperature: keep in original packaging, protect from light and moisture.

Palonosetron may interact with several drug classes.

Major Interactions (Avoid): - Class I anti‑arrhythmic agents (Cytotoxic C        ). - Medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         ​

Moderate